Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-046: ADXS31-142 +/- Pembrolizumab in mCRPC
NCT02325557Phase 2Completed
- Sponsor
- Advaxis, Inc.
- Start
- Jun 2015
- Primary completion
- Aug 2019
- Modality
- Oncolytic Viruses, Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ADXS31-142 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Advaxis, Inc. Primary endpoint: Treatment-Emergent Adverse Events. Started Jun 2015; status: completed.
02
Drugs
ADXS31-142
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02325557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325557.